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3. ABBREVIATIONS 
 
11-HSD1   11--hydroxysteroid dehydrogenase type 1 
2h-PG    2-hour post-challenge plasma glucose 
A1C    Haemoglobin A1C 
ADA    American Diabetes Association 
AUC    Area under the curve 
BMI    Body mass index 
CKD    Chronic kidney disease 
CNI    Calcineurin inhibitor 
CsA    Cyclosporine A 
DBN    Diabetic nephropathy 
DM    Diabetes mellitus 
ESRD    End stage renal disease 
FPG    Fasting plasma glucose 
GFR    Glomerular filtration rate 
GR    Glucocorticoid receptor 
GRE    Glucocorticoid responsive element 
HGO    Hepatic glucose output 
IFG    Impaired fasting glucose 
IGT    Impaired glucose tolerance 
IR    Insulin resistance 
ISec    Insulin secretion 
MAR    Missing at random 
MCAR   Missing completely at random 
MNAR   Missing not at random 
NODAT   New onset diabetes mellitus after transplantation 
OGTT    Oral glucose tolerance test 
PHYG    Posttransplant hyperglycaemia 
PTH    Parathyroid hormone 
ROC    Receiver operating characteristic 
RTx    Renal transplantation 
WHO    World Health Organization 
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5. INTRODUCTION 
 
Renal transplantation (RTx) is the best treatment option for end stage renal disease (ESRD) 
(1). In the early days of clinical transplantation, early graft rejection was the most important 
clinical problem after RTx. Modern immunosuppressive drugs have significantly reduced the 
magnitude of this problem, and shifted the focus towards improving the long term patient and 
graft outcomes. Increasing efforts are thus being made to lower the burden of cardiovascular 
disease, which is a major cause of death in RTx patients (2;3). The increased cardiovascular 
risk in RTx patients seems attributable to traditional risk factors such as old age and male 
gender, but also to abnormalities in glucose regulation occurring after RTx (3;4). 
Diabetes mellitus (DM) and other abnormalities in glucose regulation are common 
after RTx. This is often to be expected, since patients with diabetic nephropathy (DBN) or 
other long-standing DM before RTx will normally continue to have DM after surgery. 
However, even in non-diabetic populations, ESRD predisposes to pretransplant glucose 
intolerance by being an insulin resistant state (5). This predisposition often becomes apparent 
after RTx, when the incidence of DM increases (6). Some 10-20% of the patients without 
pretransplant DM develop new onset DM after RTx (NODAT), and 20-40% have milder 
forms of hyperglycaemia (7). 
 
5.1. Epidemiology of hyperglycaemia 
 
The global burden of hyperglycaemia has reached epidemic proportions. As defined by the 
World Health Organization (WHO) criteria for hyperglycaemia, it is estimated that 285 
million people have DM worldwide (6.4%), and that 438 million will have the disease by 
2030 (8). Type 2 DM is estimated to account for more than 90% of all cases of DM. Only 
some 50% of all prevalent cases of DM have been diagnosed, with the highest proportion 
diagnosed in North America (70%) and the lowest in Africa (30%). In addition to DM, 344 
million people are estimated to have impaired glucose tolerance (IGT), corresponding to 
roughly 8% of the world adult population. Compared to DM and IGT, the prevalence of 
impaired fasting glucose (IFG) is less well examined. The overall prevalence has been 
estimated to roughly 5% using the WHO criteria (9;10). As compared to these criteria, the 
former American Diabetes Association (ADA) criteria were thought to raise the apparent 
prevalence of IFG by a factor of two to three (9). Accordingly, a 15% prevalence was recently 
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reported (11). No large studies have been performed, however, subsequent to the recent 
modification of diagnostic criteria introduced by the ADA as of January 2010 (12). 
 DM leads to macro- and microvascular complications. The all-cause mortality rate in 
patients with DM is two to four times higher than in the general population, much due to 
macrovascular disease, which accounts for roughly 50% of all deaths in these patients (13). 
Diabetic retinopathy is the leading cause of blindness in adults below 75 years of age in 
developed countries, and occurs in more than 60% of patients with DM within 15-20 years of 
diagnosis (14). Peripheral neuropathy affects an estimated 20% of diabetic patients (15). 
Between 12% and 45% of incident ESRD is due to DM worldwide, making DM the most 
common cause of ESRD in countries such as the U.S., Japan and Korea (16). The incidence of 
ESRD due to type 2 DM is reported to increase by 10% annually in some regions (17;18). 
 
5.2. Pathophysiology of hyperglycaemia 
 
The maintenance of normal glucose homeostasis requires a precise regulation of glucose 
production and disposal. Insulin facilitates the tissue uptake of glucose and suppresses 
glucose production, and is therefore the key regulator of glucose homeostasis. Defects in 
insulin action or secretion can result in insufficient disposal of glucose, an excessive 
production of glucose, or a combination of both factors, leading to hyperglycaemia. 
In the fasting state, hyperglycaemia is primarily thought to reflect an elevated glucose 
production. This can occur if glucose-producing organs are resistant to the anti-gluconeogenic 
effect of insulin, or if insulin levels are insufficient to suppress the production of glucose. 
Postprandial hyperglycaemia mainly results from a reduced glucose disposal secondary to 
varying degrees of insulin resistance (IR) and impaired insulin secretion (ISec) (19;20). The 
proposed pathogeneses of fasting and postprandial hyperglycaemia are illustrated in Figure 1. 
DM is a diverse group of disorders characterized by defects in insulin secretion (type 1 
DM) and most often also insulin sensitivity (type 2 DM), leading to overt forms of fasting or 
postprandial hyperglycaemia, or a combination of both. Type 1 DM results from a progressive 
destruction of pancreatic  cells, whereas type 2 DM arises in a combined context of IR and 
impaired ISec. The development of DM is commonly thought be preceded by a period of 
intermediate degrees of hyperglycaemia. These are termed IFG or IGT, depending on whether 
fasting or postprandial hyperglycaemia is clinically predominant. The transition from 
intermediate hyperglycaemia to DM is often explained by increasing defects in ISec (21). In 
the development of type 2 DM, IR is often considered the initial defect. In the presence of IR,  
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Figure 1. Contribution of different glucose compartments in glucose homeostasis. 
A. Normal fasting state. Hepatic glucose output (HGO) is the main source of glucose. B. Normal postprandial 
state. Oral intake is the main source of glucose. Insulin facilitates peripheral and hepatic glucose uptake, and 
suppresses HGO. C. Fasting hyperglycaemia. HGO is increased due to insulin deficiency or hepatic insulin 
resistance (IR). In the presence of peripheral IR or insulin deficiency, this results in hyperglycaemia. 
Peripheral glucose uptake is increased by an insulin independent mass effect to accommodate the increased 
glucose output (22). D. Postprandial hyperglycaemia. IR or insulin deficiency results in reduced peripheral 
and hepatic insulin mediated glucose uptake, as well as in sustained HGO, leading to hyperglycaemia. Oral 
intake is the dominant source of glucose, although HGO also contributes. The glucose mass effect ensures a 
maintained peripheral glucose uptake despite the insulin resistance or deficiency (23). [Schematic figure 
created by HA Bergrem. The magnitude of the contribution from each compartment is subject to debate; 
arrow thicknesses should be interpreted accordingly. Glucagon and other substances are omitted for clarity.] 
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overt DM is avoidable through a compensatory hypersecretion of insulin in the early phases 
of the disease. Once  cell function deteriorates, DM becomes clinically manifest. 
 
5.3. Hyperglycaemia in end stage renal disease 
 
5.3.1. Epidemiology 
 
The prevalence of undiagnosed hyperglycaemia (DM or intermediate hyperglycaemia) among 
ESRD patients has not been studied in large populations. Small studies have indicated a 
prevalence of undiagnosed hyperglycaemia in the range of 30-50% as determined by the oral 
glucose tolerance test (OGTT) (24;25). The prevalence of acknowledged DM was 33% 
among all patients entering renal replacement in Norway in 2008 (26). In the majority of these 
patients (55%), DM was listed as the primary cause of ESRD. Although similar figures have 
been reported in other countries (18), the overall prevalence of acknowledged DM in ESRD 
(i.e. DM with or without DBN) is likely to display significant geographical variability.  
Due to the lack of studies examining intermediate hyperglycaemia and undiagnosed 
DM, the prognostic implication of these conditions in ESRD is largely unknown. Increased 1-
year mortality rates have been described in hemodialysis patients with IFG as compared to 
otherwise comparable patients having normal glucose levels (27). As for patients with 
acknowledged DM at the time of receiving the ESRD diagnosis, a significant excess mortality 
risk is observed as compared to patients with ESRD and no DM (18). Macrovascular disease 
accounts for nearly half of all deaths in diabetic ESRD patients (17). RTx confers a significant 
survival benefit in ESRD patients with type 1, and probably also type 2 DM (28). 
 
5.3.2. Pathophysiology 
 
Reduced renal function is associated with abnormal glucose metabolism even in the absence 
of DM (29). IR and increments in postprandial plasma glucose are inversely related to 
glomerular filtration rate (GFR) in subjects with normal glucose tolerance and mild to 
moderate chronic kidney disease (CKD) (30). The presence of IR is more pronounced among 
patients having GFR levels below 50 mL/min/1.73m2 (31), and is nearly universal in ESRD 
(5). Nonetheless, IR is often compensated by increments in ISec, and also by the reduction in 
insulin clearance that accompanies renal failure in advanced CKD. This leads to elevated 
fasting insulin levels that are capable of controlling the degree of fasting hyperglycaemia (32). 
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Even though IR and renal dysfunction are related, both the nature and direction of this 
relationship are unclear. The presence of IR may damage the kidneys through pathways 
involving inflammation, either directly or via mechanisms related to other cardiovascular risk 
factors, such as old age, obesity, hypertension or dyslipidaemia (30;33). It is well known, 
however, that the insulin sensitivity in ESRD patients improves following hemodialysis, and 
that the improved glucose tolerance remains improved for up to one week after cessation of 
hemodialysis (34). This strongly suggests that IR in uraemic patients is related to factors that 
are specific to renal failure. Among several possible risk factors (Table 1), nitrogenous 
compound retention is at present the dominant hypothesis; it supports the role of a dialysable 
solute, and the insulin-sensitizing effects of low-protein diets in uraemia (35).  
 
Table 1. Risk factors for insulin resistance in uraemia 
General  Uraemia related 
Age  Nitrogenous compound retention (36;37) 
Ethnicity  Protein energy wasting (38) 
Obesity  Vitamin D deficiency (39) 
Family history  Metabolic acidosis (40) 
Hypertension  Anaemia (41) 
Dyslipidaemia  Calcium-phosphate derangements (42;43) 
  Secondary hyperparathyroidism (44) 
 
 
Abnormalities directly affecting ISec are less consistently present as compared to the 
defects in insulin sensitivity and clearance in ESRD (45;46). Nonetheless, as in type 2 DM,  
cell defects are often involved in cases of overt hyperglycaemia (47). The pathogenesis of 
these defects is nonetheless poorly understood. While some studies have suggested that 
hyperparathyroidism or hypocalcaemia could impair ISec (42;46;48;49), other studies have 
disputed these findings (44;50-53). The altered metabolism of incretins in CKD could play a 
role (54). It is also likely that reduced ISec in ESRD is related to old age, genetic factors and 
toxic effects of hyperglycaemia, free fatty acids or other substances (21), as it is in type 2 
DM. 
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5.4. Hyperglycaemia after renal transplantation 
 
5.4.1. Epidemiology 
 
The incidence of DM after RTx is higher than before RTx (6). Accordingly, a considerable 
proportion of patients develops NODAT. Although reported incidences vary widely (55), it 
may be assumed that some 10-20% of the patients develop NODAT, and that 20-40% have 
intermediate hyperglycaemia (7). The incidence of NODAT is highest during the initial few 
months after RTx, and declines gradually thereafter (6;56-59). 
NODAT is associated with increased mortality (57;60-62), primarily through 
macrovascular disease, which accounts for 30-50% of all deaths in RTx patients (3;16;63). 
NODAT may also increase the risk of graft loss (57;61) and non-fatal macrovascular events 
(61;63;64). The spectrum of diabetic complications due to NODAT is otherwise similar to 
that observed for type 2 DM, but complications appear to occur at a higher rate (65). As in the 
general population, even non-diabetic levels of hyperglycaemia have been associated with 
increased mortality and morbidity in RTx patients (4;66).  
 
5.4.2. Pathophysiology 
 
Even though RTx helps restore renal function, patients continue to display IR after RTx (67). 
This creates a sustained demand for compensatory elevations in ISec, which is further 
augmented by the increased renal clearance of insulin that accompanies restoration of renal 
function. The maintenance of normoglycaemia after RTx therefore places high demands on  
cell function. Accordingly, an insufficient residual  cell capacity is a key component in the 
development of overt posttransplant hyperglycaemia (PHYG) (68;69).  
As illustrated in Table 2, PHYG is associated with both pre-existing and RTx related 
risk factors (7;55;70-72). Among these factors, immunosuppressive therapy arguably 
constitutes the single most important factor (55). Prednisolone and calcineurin inhibitors 
(CNIs) predispose to NODAT, and probably also intermediate hyperglycaemia (59;73-75). 
Inhibition of ISec appears to be the main mechanism by which CNIs exert their diabetogenic 
effect (76;77). Prednisolone may also inhibit ISec to some extent, but primarily induces IR in 
skeletal muscle and liver, leading to impaired glucose disposal and increased glucose 
production (78). Within the group of pre-existing factors, pretransplant glucose levels provide 
information that may not be fully accounted for by traditional risk factors (79-82).  
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Due to the restoration of renal function, it may not be expected that hyperglycaemia 
should correlate with similar risk factors after RTx as in ESRD. Nonetheless, renal function is 
not normal after RTx, and neither is the metabolism of substances such as calcium, phosphate, 
parathyroid hormone (PTH), haemoglobin or nitrogenous compounds (collectively termed 
‘CKD related factors’ in Table 2). It may therefore be premature to conclude that these 
substances only relate to hyperglycaemia in ESRD. Surprisingly, the role of these substances 
has not previously been addressed in relation to PHYG.  
 
Table 2. Risk factors for posttransplant hyperglycaemia 
Pre-existing  Transplant related 
Age 
 
CNI 
Ethnicity 
 
Steroids 
HCV 
 
Acute rejection1 
Family history1 
 
Increased insulin clearance1 
Obesity1 
 
HLA mismatch1 
Pretransplant glycaemia1 
 
Donor vital status1 
CMV1 
 
CKD related factors1,2 
1These factors have been reported, but are still under debate. 
2Commonly encountered abnormalities related to renal function, such as altered metabolism of calcium, 
phosphate, PTH, haemoglobin, urea/nitrogenous compounds  and other substances 
 
 
5.4.3. Role of prednisolone 
 
The risk of PHYG depends on the prednisolone dose, and can be lowered by prednisolone 
dose reductions (74;83). Low-dose steroid or steroid free immunosuppressive regimens have 
thus become increasingly common. Nonetheless, these strategies may increase the risk of 
acute rejection (71). It is also unlikely that dose reductions can eliminate the empirical inter-
subject variability in the occurrence of prednisolone effects and side effects, which is even 
observed between subjects receiving the same weight adjusted doses of prednisolone. This 
suggests that better tools are needed to determine the optimal prednisolone dosage in 
individual patients. In RTx recipients, this task is complicated by the possibility that the 
metabolism of prednisolone may interact with that of other immunosuppressive drugs (84).  
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The inter-subject variability of prednisolone effects and side effects may partly be 
attributable to its unusual pharmacokinetics. The protein binding of prednisolone decreases 
non-linearly from 95% to 60%–70% as the total concentration increases from 200 ng/mL to 
800 ng/mL. At low concentrations (200 ng/mL), prednisolone binds mainly to plasma 
transcortin, while at higher concentrations, it increasingly binds to albumin (85). The non-
linear protein binding coincides with the observation that certain parameters in prednisolone 
pharmacokinetics, such as the clearance of unbound drug, have been found dose independent 
(86). This is likely to have clinical relevance, since biological effects of prednisolone are 
believed to be exerted by the unbound fraction of the drug (87). Low albumin levels are 
associated with reduced protein binding and increased glucocorticoid side effects in systemic 
lupus erythematosus (88), celiac (89) and inflammatory bowel disease (90). The concentration 
of unbound prednisolone is increased in RTx recipients, due to reduced renal or hepatic 
clearance (91). Similar findings have been made in liver and lung transplant recipients (92).  
The potentially variable combined effects of non-linear protein binding and renal or 
hepatic impairment create a rationale for prednisolone concentration monitoring after RTx. 
However, the research effort relating to such monitoring has been very small for prednisolone 
as compared to more modern immunosuppressive agents (93). Nonetheless, prednisolone 
meets several of the requirements proposed for therapeutic drug monitoring (87). First, the 
time from dosing until the appearance of side effects is often long. Second, the therapeutic 
index of prednisolone is sufficiently narrow to warrant monitoring. Third, the requirement for 
prednisolone is usually prolonged in RTx recipients. Fourth, reliable methods for measuring 
prednisolone are available. Finally, a direct association between prednisolone concentration 
and effects can be demonstrated for several outcomes. Such a relationship has not, however, 
been demonstrated between prednisolone and posttransplant glycaemia. 
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6. AIMS OF THE STUDIES 
 
An optimal handling of posttransplant glucose intolerance requires a broad understanding of 
glucose abnormalities occurring both before and after RTx. The primary goals of the present 
work were to shed new light on the natural history of glucose tolerance before and after RTx, 
and to examine some risk factors for the development of posttransplant hyperglycaemia. 
 
6.1. Paper 1 
 
No epidemiological studies have formally assessed both fasting and postprandial glucose to 
identify patients with hyperglycaemia before RTx. We aimed to determine the prevalence of 
undiagnosed DM and intermediate hyperglycaemia in renal transplant candidates, and also to 
study how patients with undiagnosed DM may most effectively be identified. 
 
6.2. Paper 2 
 
The presence of subtle glucose abnormalities before RTx has been found to translate into an 
increased risk of PHYG. We wanted to verify this finding in a large population, and also 
address whether the predictive effect of pretransplant glycaemia could be different for fasting 
and postprandial glucose. In addition, we aimed to examine whether hyperglycaemia may 
have common metabolic denominators in uraemic and transplanted populations. 
 
6.3. Paper 3 
 
Although the diabetogenic effect of prednisolone after RTx is dose related, there is great 
variability in the occurrence of glucose intolerance between subjects receiving the same 
prednisolone dose. We wanted to investigate whether the effect of prednisolone on glucose 
tolerance may be more precisely evaluated through pharmacokinetic rather than strictly dose 
related parameters. Specifically, we studied whether the exposure to unbound prednisolone, 
the biologically active component of prednisolone, is associated with glucose tolerance. 
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7. PATIENTS AND METHODS 
 
7.1. Study population and design 
 
The present work contains three articles investigating glucose tolerance in relation to RTx. In 
these papers, glycaemia is assessed before RTx (Paper 1), before and short term after RTx 
(Paper 2), and long term after RTx (Paper 3). 
 
7.1.1. Paper 1 
 
This is a cross-sectional population based study of glucose metabolism at the time of referral 
for RTx in non-diabetic RTx candidates in Norway. All adult patients with non-diabetic 
ESRD referred from renal units in Norway to Rikshospitalet University Hospital for a 1st 
single RTx between September 2002 and February 2009 were eligible (n=1111). Patients with 
known DM prior to referral were excluded (n=77), along with patients having incomplete 
pretransplant glucose data (n=145). A total of 889 patients were therefore included. Patients 
and their data were identified using the hospital records of Rikshospitalet University Hospital. 
All patients provided a written informed consent for the use of their data, and the project was 
performed in accordance with the Declaration of Helsinki. 
 
7.1.2. Paper 2 
 
This is a retrospective cohort study of risk factors for PHYG early after RTx. Specifically, the 
role of pretransplant glycaemia and correlates of posttransplant renal function were examined. 
The incidence of NODAT was recently addressed in a report on patients who underwent RTx 
in Norway between October 2003 and October 2005 (94). Extended data from this cohort 
were made available for our analysis. Among all eligible patients (n=500), we included all 
adults who attended the posttransplant follow-up and were without overt pretransplant DM 
(n=301). Overt pretransplant DM was defined as having known DM before the RTx work-up 
(with or without DBN), alternatively as the initiation of glucose lowering drug therapy 
between work-up and RTx. The study cohort contained a subset of patients who were studied 
in Paper 1 (n=257), in addition to 44 patients receiving a re-transplant. Patients and their data 
were identified using the hospital records of Rikshospitalet University Hospital. All patients 
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provided a written informed consent for the use of their data. The project was approved by the 
local Data Inspectorate and performed in accordance with the Declaration of Helsinki. 
 
7.1.3. Paper 3 
 
This is a cross-sectional study of the association between prednisolone pharmacokinetics and 
glucose tolerance in stable RTx recipients. Patients were recruited from the outpatient clinic at 
Rikshospitalet in 1980-81, and included all adult outpatients having non-diabetic renal 
disease, no current DM, a stable graft function and 6 months of follow-up (n=187). Patients 
were examined at a median of roughly 5 years posttransplant, and constituted some 50% of all 
non-diabetic RTx recipients alive in Norway at the time. Based on these data, a report was 
published in 1985 on the pharmacokinetics of prednisolone in this population (95). A number 
of patients also agreed to perform an OGTT during the study (n=131). These data were not 
given priority in the report published in 1985, but have now been re-analyzed to include the 
unpublished OGTT. After excluding subjects taking prednisolone twice daily (n=21) or 
having an extreme 2-hour post-challenge plasma glucose (2h-PG; >19 mmol/L, n=2), 108 
patients (41 females, 67 males) were included. All used prednisolone, in combination with 
either azathioprine (n=99) or cyclophosphamide (n=9). Participation was voluntary and based 
on informed consent. The present reanalysis of historical data was approved by the Southern 
Norway Regional Committee for Medical Research Ethics. 
 
7.2. Glucose measurements 
 
7.2.1. Paper 1 
 
Along with a résumé of each patient’s medical history, the referral for RTx in Norway 
contains a standardized work-up form reporting the result of a pretransplant standard 75g 
OGTT that is mandatory in all patients without acknowledged DM. The OGTT is analyzed 
according to local hospital standards and should include a specification of the test material 
used (plasma vs. whole blood).  Unfortunately, a specification of the test material used was 
lacking in some 90% of patients. We therefore asked referring centres to provide written 
information on the material used within specific time periods. All centres were subsequently 
contacted per phone to confirm the information provided. The information was used to 
specify a test material for each patient lacking such data. In 81 patients, the OGTT result was 
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reported in venous whole blood rather than plasma. These results were converted to plasma 
equivalent values through multiplication by a factor of 1.11 (96). 
 
7.2.2 Paper 2 
 
Pretransplant OGTT data were retrieved as described for Paper 1. Whole blood results were 
only reported in two patients, and results were considered plasma equivalent. 
At follow-up 10 weeks posttransplant, all patients underwent a repeat OGTT at our 
centre, except if DM had been diagnosed between RTx and follow-up. This OGTT was 
analyzed in venous whole blood by a modified glucose dehydrogenase method. Results were 
classified according to WHO whole blood criteria for hyperglycaemia (see below) (97), but 
reported as plasma equivalent in the published article (96). 
 
7.2.3. Paper 3 
 
Participants were admitted for a 3-day inpatient data collection. On the morning of day 2, 
prednisolone analyses were performed as described below. On the morning of day 3, a 
standard 75g OGTT was performed with venous plasma glucose measured at 30-minute 
intervals using an enzymatic colorimetric glucose oxidase method. Glucose tolerance was 
assessed using 2h-PG or glucose area-under-the-curve (AUC) calculated by the trapezoid rule. 
 
7.3. Classification of glucose tolerance 
 
The classification of patients into categories of glycemia is intended to delineate transitions in 
the risk for complications of hyperglycaemia and progression to overt DM. The WHO and 
ADA diagnostic criteria differ with respect to IFG and normal fasting glycaemia, and as of 
year 2010 even with respect to the use of haemoglobin A1C (A1C) for diagnosing DM. The 
WHO criteria were used in Paper 3, and also for the pretransplant values in Paper 2 and the 
current summary of all three papers [DM: fasting plasma glucose (FPG) 7.0 mmol/L or 2h-
PG 11.1 mmol/L; IGT: FPG <7.0 mmol/L and 2h-PG 7.8-11.0 mmol/L; IFG: FPG 6.1-6.9 
mmol/L and 2h-PG <7.8 mmol/L; normal glycaemia: FPG <6.1 mmol/L and 2h-PG <7.8 
mmol/L] (9). The posttransplant values in Paper 2 were analyzed in venous whole blood, and 
classified accordingly using the WHO criteria for whole blood (DM: fasting glucose 6.1 
mmol/L and/or 2-h glucose 10.0 mmol/L; IGT: fasting glucose <6.1 mmol/L and 2-h 
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glucose 6.7–9.9 mmol/L; IFG: fasting glucose 5.6–6.0 mmol/L and 2-h glucose <6.7 mmol/L; 
normal glycaemia: fasting glucose <5.6 mmol/L and 2-h glucose <6.7 mmol/L) (97). In Paper 
1,  the 2003 ADA criteria were used [IFG (FPG 5.6-6.9 mmol/L and 2h-PG <7.8 mmol/L); 
normal glycaemia (FPG <5.6 mmol/L and 2h-PG <7.8 mmol/L); IGT and DM as in WHO 
criteria for plasma samples] (98). In the 2010 ADA classification, these criteria have been 
extended to also include the possibility to diagnose DM by A1C6.5% in patients with 
normal red cell turnover (12). Although the latter is often not the case in patients with ESRD, 
the 2010 ADA criteria were briefly explored in the present summary of Paper 1 (not in the 
accepted article). Patients having DM, IGT or IFG were defined as having hyperglycaemia. 
 
7.4 Other investigational procedures 
 
7.4.1. Paper 1 
 
In addition to the pretransplant OGTT, other data were extracted from the referral and work-
up forms: age, gender, ethnicity, body-mass-index, renal diagnosis, prednisolone use, dialysis 
mode and duration, haemoglobin, albumin, total cholesterol, A1C, FPG and 2h-PG. 
 
7.4.2. Paper 2 
 
In addition to the pre- and posttransplant OGTT, several correlates of posttransplant renal 
function were assessed. Measurements were performed at the 10-week follow-up at our 
centre, and included a measurement of GFR (51Cr-EDTA methods), haemoglobin 
(cyanomethemoglobin methods), phosphate (ammonium molybdate methods), intact PTH 
(chemiluminescence immunoassays), ionised calcium (potentiometric methods), urea (urease-
glutamate dehydrogenase methods) and creatinine (creatinase methods). 
 
7.4.3. Paper 3 
 
On the morning of day 2, fasting blood samples were drawn for baseline prednisolone and 
routine laboratory tests. Oral prednisolone was then given according to each subject’s regular 
regimen. Prednisolone was measured at 0, 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours. At each time 
point, the total prednisolone concentration was analyzed with a specific radioimmunoassay, in 
which serum was incubated with anti-prednisolone antibodies and [3H]-labelled prednisolone. 
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Bound and unbound prednisolone were separated in a charcoal suspension, followed by a 
measurement a radioactivity in the supernatant. The protein binding of prednisolone was 
studied by equilibrium dialysis, in which serum was dialyzed against a [3H]-prednisolone 
containing buffer. The fraction of protein-bound prednisolone at equilibrium was calculated 
as (serum dpm-buffer dpm)/serum dpm (dpm=disintegrations per minute of [3H]). 
 
7.5. Statistical analysis 
 
7.5.1. General considerations 
 
7.5.1.1. Missing data 
 
All clinical research is potentially subject to information bias due to missing data. Participants 
may refuse to perform a particular test, and investigators may omit a test, intentionally or not, 
or forget to record a test result. The lack of data usually follows patterns, although these are 
often unapparent. Measurements of glucose, for instance, may be more often missing in 
young compared to older subjects. This can be due to a perception that such measurements are 
less important among young patients, since they have a lower prevalence of DM. This creates 
a situation where the missing glucose data are systematically different (in this case lower) 
than the observed data, leading to potential bias. Failure to recognize the mechanisms leading 
to missing data can have a large impact on the internal validity of the results in a study. 
Until recently, the presence of missing data has been difficult to handle statistically. 
All statistical models require complete data sets, and subjects with incomplete data have 
commonly been excluded from the analysis (complete case analysis). Unfortunately, this 
approach is only satisfactory when there is no underlying pattern explaining the lack of data 
(i.e. data are missing completely at random, MCAR) (99;100). This is rarely the case, 
however, and complete case analysis is normally inadvisable unless the proportion of patients 
having missing data is below 5-10% (99;101). When missing data are not MCAR, they can 
follow one of two patterns, namely missing at random (MAR) or missing not at random 
(MNAR) (99-101). The presence of a MAR pattern indicates that, although the missing data 
may be systematically different from the observed data, this difference can be explained by 
other variables in the data set. For instance, if missing glucose values are lower than the 
observed glucose values, this may be related to the age of patients. Young patients may be 
less likely to have glucose measured, and simultaneously happen to have lower glucose 
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levels. In this example, systematic differences for missing glucose can be explained by age, 
and MAR is present given that both glucose and age are recorded variables in the data set. 
The MNAR pattern differs from the MAR pattern in that the systematic differences can only 
be explained by factors that are not recorded in the data set. For instance, an MNAR pattern 
would exist if only young patients have missing data, and we have not recorded the age of the 
patients. MAR and MNAR patterns can not be distinguished mathematically, and the presence 
of a MAR pattern can only be assumed, not proved. However, the likelihood that a MAR 
pattern is present, i.e. that the observed variables explain why data are missing, increases with 
the number of recorded variables in a data set (100;102). 
 
7.5.1.2. Multiple imputation 
 
When a MAR pattern can be assumed present, and the proportion of subjects having missing 
data is not too high (>60% has been suggested), data can be analyzed using multiple 
imputation (99;100;102;103). This is a statistical procedure designed to minimize the bias 
introduced by missing data, and has become an integral part of most statistical computer 
programs. Imputation refers to the replacement of missing data with statistically probable 
values. This replacement can prevent investigators from having to exclude subjects with 
incomplete data, and thereby enable the statistical power to be maintained as compared to 
complete case analysis. The values used to replace missing data are generated using 
regression models taking all other variables in the data set into consideration. For instance, if 
age, body mass index (BMI) and blood pressure, but not glucose, is known for a patient, the 
glucose can be estimated based on a combination of the patient’s age, BMI and blood 
pressure, as well as the age, BMI, blood pressure and glucose values of all other participants. 
However, since the estimated values are only based on probabilities, some of the estimated 
values may be far from the “true” unobserved value, and may therefore introduce additional 
bias. For this reason, it is preferable to do multiple imputations, rather than a single one. By 
doing multiple imputations, the generated values are allowed to differ from one imputation to 
the next, reflecting the inherent uncertainty with which missing data are replaced. In multiple 
imputation, one therefore ends up having a number of different copies of the original data set, 
in which missing data have been replaced by different, and yet statistically probable values 
from one imputed data set to the next. To capture the uncertainty involved when replacing 
missing values, it is often recommended that 10 imputed data sets are created (99;102;103). 
Statistical analyses can then be performed separately on each imputed data set, upon which 
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the separate results from each data set are pooled to yield the final result of multiple 
imputation. The strength and final aim of multiple imputation is therefore not to replace 
missing values per se, but rather to create a more valid overall impression of the associations 
between variables than has been possible with traditional methods for handling missing data. 
 
7.5.2. Final analyses 
 
In papers 1 and 2, 45% and 28% of patients had 1 missing data entry, respectively. In both 
papers, the presence of a MAR pattern for missing data was found to be probable. In Paper 3, 
the prevalence of missing data was low (<10%). Multiple imputation was therefore applied 
prior to statistical analysis in Papers 1 and 2 as detailed in each respective paper. 
Data are presented as mean (standard deviation), median (interquartile range) or 
frequencies (%). Groups were compared using parametric (paired or unpaired t-test; 
ANOVA), rank-based (Mann-Whitney; Wilcoxon signed rank; Jonckheere-Terpstra) or 2 
methods, with Fisher’s exact methods as appropriate (2x2 tables with expected cell 
frequencies <5). Bonferroni corrections were used for multiple comparisons. Continuous 
variables were compared using parametric (Pearson's r) or non-parametric correlations 
(Spearman's Rho). For all analyses in the present work, two-tailed p values <0.05 were 
considered statistically significant. Analyses were implemented in SPSS versions 13 and 17. 
 
7.5.2.1. Paper 1 
 
Patients were classified as having undiagnosed DM, IGT, IFG or normal glycaemia. The 
prevalence of undiagnosed hyperglycaemia or DM was compared to the general population by 
indirect standardization methods, applying the DECODE prevalence rates for each gender and 
10-year age interval (104). The standardized morbidity ratio (SMR) is reported, and a value 
>1 indicates a greater burden of disease. Fasting and postprandial classifications were cross-
tabulated to visualize the prevalence of hyperglycaemia by each modality. Receiver operating 
characteristic (ROC) analysis was applied among patients having a non-diabetic FPG in order 
to assess the accuracy of FPG or A1C for predicting a diabetic 2h-PG. To assess the impact of 
the 2010 ADA classification for DM, ROC analyses were subsequently repeated among 
patients having non-diabetic values for both FPG and A1C (<6.5%). Specific methods relating 
to the ROC analyses are detailed in the Paper 1 article. 
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7.5.2.2. Paper 2 
 
Multiple logistic regression was used to study risk factors for PHYG. Explanatory variables 
were selected a priori, and included the pretransplant OGTT result (FPG or 2h-PG), metabolic 
correlates of posttransplant renal function (urea, phosphate, ionized calcium, PTH, GFR), as 
well as confounders and known risk factors. The contribution of pretransplant glycemia to the 
occurrence of PHYG was assessed using the log likelihood method for comparing models 
including or excluding pretransplant glucose data. 
 
7.5.2.3. Paper 3 
 
Multiple linear regression was used to study risk factors for reduced glucose tolerance. 
Explanatory variables were selected a priori and included the AUC of unbound prednisolone, 
alternatively the daily prednisolone dose, and other established risk factors. 
 26 
8. RESULTS 
 
8.1. Paper 1 
 
Undiagnosed hyperglycaemia before RTx was observed in 326 (37%) patients [WHO criteria; 
72 DM (8%), 230 IGT (26%), 24 IFG (3%)]. A minority of the patients were receiving 
dialysis treatment prior to the referral (n=349, 39%). These patients had lower FPG and A1C 
levels as compared to predialytic patients [5.1 vs. 5.2 mmol/L and 5.4 vs. 5.6 %, 
respectively). 
The diagnosis of DM required an OGTT in 56 of 72 cases (78%), as only 16 of 72 
patients (22%) with diabetic glycaemia were diabetic by FPG criteria alone. The majority 
(78%) of the diabetic patients would therefore be classified as non-diabetic if the OGTT were 
to be omitted. Some 50% of the diabetic patients would also have been classified as non-
diabetic if the OGTT were to be restricted to patients having IFG. 
In the ROC analysis, FPG was an accurate predictor of a diabetic 2h-PG (AUC 0.734, 
95% CI 0.674-0.795). When restricted to patients having FPG 5.1-6.9 mmol/L, the OGTT 
identified 80% of patients with a diabetic 2h-PG alone (49 of 56 patients; 88%). Overall, this 
stepwise procedure (FPG followed by OGTT in selected patients) identified 65 of 72 patients 
with undiagnosed DM (90%; 16 by FPG, 49 by 2h-PG), and required an OGTT in 463 of 873 
patients (53%) with a non-diabetic FPG. These results were consistent among the predialytic 
patients as well as in patients on dialysis, and were essentially the same when ROC analyses 
were restricted to patients having both FPG<7.0 mmol/L and A1C<6.5% (ADA 2010 
criteria). 
In contrast to FPG, ROC results indicated that A1C could not be used as a general tool 
to identify patients who should proceed to a diagnostic OGTT (AUC 0.578, 95% CI 0.482-
0.673). The accuracy improved when studied in predialytic patients alone, but did not surpass 
that of FPG even here [AUC 0.689 (95% CI 0.586-0.791) vs. 0.710 (95% CI 0.624-0.795); 
A1C vs. FPG]. The gain from using A1C alone or combined with FPG was negligible 
whether patients had or had not been started on dialysis. The ROC results for A1C were 
consistent when restricted to patients having both FPG<7.0 mmol/L and A1C<6.5%. 
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8.2. Paper 2 
 
Ninety-three patients had PHYG (31%; 2 IFG, 52 IGT, 39 DM), most of whom were 
diagnosed by 2h-PG at follow-up (67%; 52 IGT, 10 DM). The same proportion of patients 
was found to have hyperglycaemia at the time of pretransplant referral (n=93; 5 IFG, 65 IGT, 
23 provisional DM; unpublished data). 
With each increment in pretransplant FPG or 2h-PG, the risk for PHYG increased in a 
continuous manner (p<0.001). Accordingly, pretransplant FPG and 2h-PG were higher among 
patients later diagnosed with PHYG than in patients having normal glycaemia after RTx. In 
PHYG patients, glucose handling deteriorated posttransplant (FPG 5.2 vs. 5.8 mmol/L; 2h-PG 
7.4 vs. 8.8 mmol/L; pretransplant vs. posttransplant, respectively; all p<0.001). The opposite 
was observed in patients having normal posttransplant glycaemia, where glucose handling 
improved rather than deteriorated (n=208; FPG 4.9 vs. 4.8 mmol/L; 2h-PG 6.2 vs. 5.2 
mmol/L; all p<0.001). A similar result was seen for 2h-PG in the population as a whole. 
Pretransplant levels of FPG or 2h-PG were further predictive of posttransplant urea 
levels. Patients with PHYG had higher levels of urea, but similar levels of all other 
parameters related to renal function as compared to normoglycaemic patients. Increments in 
urea were associated with a continuous increase in the risk for hyperglycaemia (p<0.001), and 
this was consistent at low, medium as well as high levels of GFR. Urea levels were related to 
some correlates of hyperglycaemia (old age, prednisolone dose and acute rejections), but also 
to male gender and correlates of renal function (phosphate, haemoglobin and GFR; all 
p<0.05). 
Increments in pretransplant glycaemia and posttransplant urea levels remained 
associated with PHYG after adjustment for important confounders and risk factors. Omission 
of pretransplant glycaemia (FPG or 2h-PG) from the statistical models did not affect the role 
of urea, but significantly reduced the models’ ability to discriminate between posttransplant 
hyper- and normoglycaemia. Comparison of models containing either FPG, 2h-PG or both 
provided a statistical indication that PHYG was more effectively predicted by pretransplant 
values of 2h-PG as compared to FPG. 
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8.3. Paper 3 
 
The median daily prednisolone dose was 10 mg (0.15 mg/kg). Due to gender differences in 
body weight, the weight adjusted daily prednisolone dose was higher among females as 
compared to males (0.17 vs. 0.14 mg/kg). Gender differences were also observed regarding 
the pharmacokinetics of prednisolone. Similar to the weight adjusted prednisolone dose, the 
Cmax and AUC of total prednisolone were higher in females as compared to males. Despite the 
higher weight adjusted prednisolone dose, however, total prednisolone clearances were lower 
among female participants. This coincided with a poorer renal function as compared to male 
subjects. Females had a lower 2h-PG as compared to males, although most results were well 
within the normal range for both genders. Accordingly, hyperglycaemia was a relatively rare 
event in this study, and was only present in 15 patients (14%; 3 DM, 11 IGT, 1 IFG). 
Reductions in glucose tolerance (increased 2h-PG or glucose AUC) correlated with an 
increasing AUC of unbound prednisolone, but not with the dose (mg/d or mg/kg/d) or any of 
the remaining pharmacokinetic parameters of prednisolone. These results were present overall 
and among males, but not in females, where glucose tolerance seemed entirely unrelated to 
prednisolone. Based on this observation, an interaction term (female*AUC prednisolone) was 
studied to explore whether prednisolone could be less diabetogenic in females as compared to 
males. In crude analysis, there was some indication that this could be the case (p=0.035). 
The crude associations between glucose intolerance and prednisolone were verified in 
multiple regression analyses adjusted for several known confounders. The AUC of unbound 
prednisolone, but not the prednisolone dose, was associated with glucose intolerance. Once 
again, this result could not be observed among females. The interaction term for gender 
specific diabetogenic effects was insignificant in multiple regression analysis and therefore 
discarded. In addition to the AUC of unbound prednisolone, glucose intolerance was 
independently associated with old age, elevated triglyceride levels and the use of furosemide. 
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9. DISCUSSION 
 
9.1. Limitations 
 
9.1.1. Definition of hyperglycaemia 
 
Although the OGTT has been emphasized for defining hyperglycaemia in the present work, 
there is controversy as to whether FPG, 2h-PG or A1C should be used for this purpose. 
Fasting and postprandial hyperglycaemia seemingly have different pathogeneses (20) and 
prognoses (105). On one hand, the 2h-PG appears to have superior accuracy for predicting 
macrovascular endpoints (106). The OGTT could thus have particular relevance in the RTx 
setting, where macrovascular disease takes a high toll on patient survival. This supported the 
use of the OGTT in the present work. On the other hand, FPG and A1C are not inferior to 2h-
PG for delineating the risk of microvascular complications (107). To the contrary, 2h-PG may 
be less convenient and repeatable as compared to A1C and FPG, and tends to overestimate 
glycaemia in single measurements (108). There is also a possibility that abnormalities in 
gastric motility contributed to this end in the present work. Delays in gastric emptying 
predispose to increments in 2h-PG (109), and are common in patients with CKD (110). The 
use of single OGTT data may thus have created flawed estimates in our studies.  
The discrete levels of glucose that should define abnormality are also debatable. The 
risk of diabetic complications begins to rise at glucose levels below those currently defined as 
diabetic, and appears to increase continuously with increasing glucose levels. The incidence 
of retinopathy begins to increase around FPG 6.1 mmol/L, A1C around 6.5%, or 2h-PG in the 
range between 8 and 10 mmol/L (107). For macrovascular outcomes, the thresholds indicating 
an increased risk have been less consistent, although it seems that current definitions of 
intermediate hyperglycaemia predict adverse outcomes in both the general (106) and RTx 
populations (4;66). As the body of evidence expands, current diagnostic thresholds will 
presumably be subject to renewed scrutiny in the future. Categories of glycaemia should thus 
be interpreted as a continuum of glycaemic excursions rather than discrete entities. 
 
9.1.2. Epidemiological methods 
 
The present work is primarily based on cross-sectional data. Such data contain no information 
on how outcomes are generated over time, which is important for studying whether causality 
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exists between two associated variables (111). Consequently, cross-sectional data can not be 
used for studying the causal mechanisms of disease, and the present work should be 
interpreted accordingly. However, cross-sectional data are useful for other purposes. They are 
effective for studying the prevalence of disease (Paper 1), and also allow hypothetical 
associations to be explored with a relatively small demand on resources (Paper 2 and 3). Such 
associations may then be studied longitudinally to assess whether an observed association 
could be causal in nature. This was only partly possible in the present work (Paper 2). 
Cross-sectional data are observational. Observational studies typically provide poorer 
information than experimental studies, since in observational studies, it is often impossible to 
control for all factors that affect the outcome. This can result in bias (systematic error). Bias 
can lead researchers to reject hypotheses that are true (type I error), or maintain hypotheses 
that are false (type II error). A bias that shifts the estimate towards the estimate stated in the 
null hypothesis (i.e. the ‘null’) is traditionally more conservative than a bias that shifts the 
estimate away from the null. Selection bias arises if the associations between variables are 
different in patients included in a study as compared to the target population. Information bias 
arises if the available information differs in quality between patients with vs. without a certain 
characteristic. This includes misclassifications, which can be differential or non-differential. 
A misclassification is differential if the probability of being misclassified follows a pattern. 
This is often the case for missing data, which fall into this category. If there is no pattern, the 
misclassification is non-differential. Finally, confounder bias results from a failure to consider 
important variables (confounders) that are known to affect each of two associated variables. 
In addition to bias, results can be affected by random errors. Random errors can be 
reduced using appropriate statistical methods and adequately sized populations. Such 
strategies are, with a few exceptions (e.g. multiple imputation), not helpful for reducing bias. 
To reduce bias, careful study designs are considerably more important. In the present work, 
random errors could be handled statistically, and probably had minor influence on results. 
Nonetheless, some degree of bias is likely to have been present. 
 
9.1.2.1. Paper 1 
 
The potential for selection bias was relatively small in this study. All referrals for RTx in 
Norway are evaluated at our centre, and each referral received within the study period was 
considered specifically. Results are likely to be representative of non-diabetic RTx candidates 
in Norway, but they should not be inferred to non-Caucasian populations. It is otherwise 
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possible that referring nephrologists may have failed to inform of a prior diagnosis of DM in 
some patients, and that the prevalence of undiagnosed hyperglycaemia was overestimated. On 
the other hand, a normal OGTT at referral may reduce the reporting of previous diabetic FPG 
results. This could in turn lead to the inclusion of presumed normoglycaemic patients, who in 
reality should have been excluded due to prior DM. This could falsely reduce the diagnosed 
prevalence of hyperglycaemia. The overall direction of selection bias was therefore unclear. 
Information bias was suggested by missing data and the imprecise reporting of the 
glucose test materials. Missing data were examined by multiple imputation and did not seem 
to influence results. Only a small number of OGTTs (n=81) were reported measured in whole 
blood. If the true number were higher, the prevalence of undiagnosed hyperglycaemia may be 
underestimated as presently reported (since whole blood results should be multiplied by a 
factor of 1.11) (96). In spite of this, the observed prevalence was high. 
 
9.1.2.2. Paper 2 
 
This study included some patients in whom undiagnosed DM was detected at referral. 
Although none of these patients were commenced on glucose lowering drugs before RTx, 
some of them may have been subjected to non-pharmacological intervention while awaiting 
RTx. This may have altered glucose levels, and thereby biased the role of pretransplant 
glycaemia. However, such interventions would tend to lower glucose levels, and move bias 
towards, rather than away from the null. Due to the small number of non-Caucasian subjects 
in our study, inference to non-Caucasian populations should be done with caution. 
A number of patients were lost to follow-up (withdrawal bias). These patients may 
have been sicker and had different levels of glucose, urea and other parameters compared to 
the included patients. Results may thus have been different in these patients. Other types of 
information bias were probably also present. Specifically, the reasons why pretransplant 
glucose data were missing in a number of patients was not entirely clear. It seems likely, 
however, that multiple imputation reduced the information bias associated with missing 
observations. Efforts were made to handle confounding by multivariable regression analysis. 
 
9.1.2.3. Paper 3 
 
In this study, various mechanisms may have lead to selection bias. Our findings are 
representative of patients selected for not having DM, and could have differed if diabetic 
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glucose levels were more prevalent. Results may also have been different among the 56 
patients who were excluded for not having consented to the OGTT. Most patients were 
studied a long time after RTx, and results could have been different at a shorter time 
posttransplant. The sum of selection biases may either have over- or underestimated our 
findings. Other types of bias (information, confounding) probably played a lesser role. The 
study was consistently planned and executed, and confounding was sought addressed using 
multivariable analysis. 
 
9.2. Interpretation of results 
 
The last few decades have seen an increased scientific and clinical interest in the development 
of glucose abnormalities after RTx. These abnormalities, and NODAT in particular, have 
serious consequences affecting both patient and graft survival (57;60-62). Many studies have 
been performed to examine the incidence of NODAT, and to identify the risk factors that lead 
to the development of this complication. 
The reported incidence of NODAT has varied widely between studies (55). While this 
partly reflects differences in the distribution of risk factors between populations, the 
variability is also attributable to differences in criteria used to define diabetes. It is 
encouraging that standard criteria for diagnosing NODAT have become established in recent 
years (70). Unfortunately, however, the same precision is rarely achieved when patients are 
classified and included in studies according to pretransplant status. Only few studies on 
NODAT have formally assessed pretransplant glucose tolerance (79-82). Instead, patients 
with pre-existing DM are typically excluded based on imprecise dichotomous data from 
charts or registries (6;57). This can alter the prevalence estimates for pre-existing DM and 
also the incidence of NODAT. The natural history of glucose tolerance in relation to RTx is 
most reliably studied using a formal assessment of glycaemia both pre- and posttransplant. In 
the present work, such measurements were available before as well as after RTx. 
 
9.2.1. Glycaemia before renal transplantation 
 
Undiagnosed hyperglycaemia and DM were prevalent in Norwegian kidney transplant 
candidates (Paper 1). Among all apparently non-diabetic patients considered eligible for RTx 
during the last 7 years, undiagnosed hyperglycaemia and DM were present in 37% and 8% of 
the patients, respectively, at the time of referral. The prevalence of hyperglycaemia would 
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have been even higher if the 2003 [n=402 (45%); 72 DM (8%), 230 IGT (26%), 100 IFG 
(11%)] alternatively 2010 ADA criteria were to be uniformly applied [n=422 (47%); 112 DM 
(13%), 214 IGT (24%), 96 IFG (11%)]. Forty-nine (6%) patients had an A1C equivalent to 
DM by the new ADA criteria (6.5%), of whom nine (18%) also met the standard DM criteria 
for glucose measurements. Consequently, the sensitivity of the A1C criteria for detecting DM 
by the glucose criteria was 13% (9 of 72 DM detected; unpublished data), indicating that A1C 
and plasma glucose criteria would identify very different subsets of patients before RTx. 
The observed prevalence of both undiagnosed hyperglycaemia and DM in the 
pretransplant population is higher than that of an age and gender standardized general 
European population from the DECODE study [SMR 1.60 (95% CI 1.43-1.79) and 1.47 (95% 
CI 1.16-1.85); undiagnosed hyperglycaemia and DM, respectively] (104). This result has not 
previously been reported in a large pretransplant population. It is unclear to which extent our 
findings could be explained by uraemic IR or other factors (e.g. differences in ethnicity, body 
composition or cardiovascular comorbidity). With one exception (haemoglobin), we had no 
data on the metabolic factors proposed to influence insulin sensitivity in uraemia, such as 
calcium, phosphate, PTH, urea, protein turnover or metabolic acidosis. Nonetheless, the 
general result in our study is in agreement with the previous observation that the incidence of 
DM is higher among ESRD patients as compared to the general population (6). 
The OGTT seemed to be of particular importance for identifying undiagnosed 
hyperglycaemia before RTx. Using WHO criteria, some 75% and 80% of all patients having 
undiagnosed hyperglycaemia and DM, respectively, would have been missed if the OGTT 
had not been performed (Paper 1). These figures are higher than those found in the general 
population, where only 40% and 30% of patients would have been missed, respectively (105). 
In morbidly obese individuals, FPG alone identified 80% of patients with undiagnosed DM 
(112). This could suggest that in uraemic patients, to a larger extent than in many other 
populations, hyperglycaemia is primarily a postprandial phenomenon. A similar observation 
has been made by others (24;113;114), but until the present work, the predisposition for 
postprandial hyperglycaemia has not been demonstrated in a large population of ESRD 
patients. The explanation for this predisposition could involve a variety of ESRD related 
factors. First, elevations in FPG may be concealed by the presence of fasting 
hyperinsulinaemia in ESRD (32). Mild cases of hyperglycaemia may therefore remain 
undetected unless formally tested using an OGTT. Second, uraemic subjects are characterized 
by peripheral IR (5), and have a reduced uptake combined with increased production of 
glucose by the liver after an oral (114) or intravenous glucose challenge (115). In subjects 
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without renal disease, peripheral IR predisposes to postprandial hyperglycaemia (20), which 
in turn may reveal or promote  cell dysfunction. This mechanism could be particularly 
pronounced in uraemic subjects, where peripheral IR is near universal. 
It is current practice in Norway to perform a pretransplant OGTT in all kidney 
transplant candidates without a prior diagnosis of DM. International guidelines propose a 
similar strategy (116). These approaches ensure a high diagnostic accuracy for pretransplant 
DM, but are also time consuming and potentially costly to incorporate into clinical practice. 
We therefore explored the accuracy of FPG as a tool to identify subjects likely to have a 
diabetic OGTT before RTx. With a minimal (10%) loss in the DM detection rate, we 
observed that restricting the OGTT to subjects with FPG 5.1-6.9 mmol/L could reduce the 
number of patients requiring an OGTT by some 50% (Paper 1). This could significantly 
reduce the time and resources required to perform the OGTT. Admittedly, however, the 
clinical significance of these findings remains unclear. First, it may not be sensible to identify 
DM pretransplant if the excess risk for PHYG is also high among patients with pretransplant 
IGT or even lower glucose levels. We (Paper 2) and others (79-82) found that the risk of 
PHYG begins to rise at non-diabetic levels of pretransplant glycaemia. Second, it is unknown 
at which thresholds and to what extent pretransplant glycaemia predicts the primary outcome 
of interest, namely the risk of posttransplant complications such as impaired patient and graft 
survival. There is also a need to clarify whether patients with vs. without pretransplant 
hyperglycaemia draw different benefits from receiving a calcineurin inhibitor with a lower 
risk of PHYG (75). 
Based on the increasing focus on the use of A1C to diagnose DM (12), we explored 
the role of A1C before RTx. A1C seemed to be of limited advantage both for diagnosis and 
case finding of DM in RTx candidates. First, the overlap was poor between A1C and standard 
glucose based criteria, as the majority (82%) of patients with DM by A1C had non-diabetic 
levels of both FPG and 2h-PG. Second, A1C seemed inappropriate for predicting a diabetic 
OGTT. This result is in contrast to those from the general population and early posttransplant 
period, where the ability of A1C to predict a diabetic 2h-PG seemed comparable to that of 
FPG (117;118). It is likely that several mechanisms contributed to these discrepancies. First, 
erythropoietin use, iron supplements, and blood loss during hemodialysis may have increased 
the turnover of red blood cells, and thereby falsely reduced A1C levels (119-121). In 
agreement with these reports, dialyzed patients in our study population were found to have 
lower levels of A1C. Second, the association between A1C and glycaemia is altered in 
uraemic patients due to the increased formation of carbamylated haemoglobin (cHb). 
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Carbamylation and glycation are competing processes occurring at similar binding sites on the 
haemoglobin molecule (122). Third, A1C and cHb have similar isoelectric points, resulting in 
a tendency of certain A1C assays, charge-based ones in particular, to report a result that in 
fact is a combined concentration of A1C and cHb (123;124). This suggests that A1C may be 
less effective as a marker of glycaemia in patients with ESRD, particularly in patients on 
dialysis, as compared to other populations. Our findings therefore align with the general 
reservations made by the ADA that A1C should not be used to diagnose DM in patients with 
abnormal red cell turnover (12). 
 
9.2.2. Glycaemia short term after renal transplantation 
 
The prevalence of PHYG and posttransplant DM at 10 weeks posttransplant were 31% and 
13%, respectively. Similar to the pretransplant setting, roughly 70% of the patients with WHO 
defined hyperglycaemia required an OGTT to be identified. This is in general agreement with 
other studies reporting a higher diagnostic yield for PHYG using the OGTT as compared to 
FPG alone after RTx (56;58;59;125). Three of these studies included an OGTT performed 
within a similar time frame as compared to our work (2-3 months posttransplant), and 
reported the incidence of NODAT to vary between 12% and 31% (56;58;125). None of the 
studies performed a formal pretransplant assessment of glucose tolerance, however, making it 
unclear to which extent the observed cases of NODAT were truly incident. In our experience, 
exclusion of the patients with provisional DM before RTx (n=23) reduced the apparent 
incidence of DM from 13% to roughly 10% (i.e. a 30% overestimation of the incidence). This 
suggests that the pretransplant OGTT is important to evaluate the true incidence of NODAT. 
The presence of PHYG was highly reflective of pretransplant glycaemia, especially 
when the latter was assessed using postprandial glucose. To our knowledge, this has not been 
observed previously. Our results may be interpreted in the light of two reports indicating that 
in non-diabetic RTx candidates, the development of PHYG is predicted by pretransplant  cell 
dysfunction rather than IR (80;82). It is thus conceivable that pretransplant 2h-PG, to a larger 
extent than FPG, was able to identify subjects with impaired pretransplant  cell function in 
our study. This possibility is supported by a recent report, where postprandial hyperglycaemia 
tended to reflect insulin hyposecretion rather than resistance in RTx candidates (113). 
An ability of 2h-PG to disclose  cell dysfunction could have clinical implications. 
First, by exposing the presence of  cell impairment, an elevated 2h-PG may identify subjects 
in whom the progression to overt DM is relatively imminent even before RTx. In the general 
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population, the combined presence of IR and insulin hyposecretion signifies a high short term 
risk of developing overt type 2 DM (126). For some patients in our study, PHYG may thus 
have resulted from a process that was already far advanced before RTx. Second, and possibly 
more important, an elevated pretransplant 2h-PG may have indicated a susceptibility to the 
diabetogenic effects of immunosuppressive drugs. Calcineurin inhibitors seem to impair  cell 
function (76;127), and could therefore be particularly unfavourable in patients who are 
already on the brink of  cell failure prior to reaching RTx (77). 
In patients who did not develop PHYG, both fasting and postprandial glucose 
improved after RTx. This may seem difficult to reconcile with the fact that all patients had 
been exposed to a significant surgical trauma and diabetogenic immunosuppressive drugs. It 
is nonetheless conceivable that the improvement in renal function after RTx in these patients 
may have caused an amelioration of the IR associated with CKD. However, IR has been 
found to diminish (80), increase (69) or remain unchanged after RTx (82). This illustrates that 
glycaemia after RTx is influenced by many other factors than renal function, such as 
immunosuppressive drugs. We did not measure insulin, and can only speculate on the factors 
that may have lead to an improvement in glycaemia in our normoglycaemic patients. 
Diminished IR, a superior  cell function, or a combination of both may have been operative. 
The levels of urea and glucose were strongly associated after RTx. In accordance, 
patients with PHYG had significantly higher levels of urea as compared to normoglycaemic 
patients. This finding has not been described before, and can have different interpretations. 
Urea may have reflected renal impairment in patients with PHYG, since renal failure reduces 
the elimination of urea and is also associated with IR (30). We believe, however, that this was 
of little importance in our study. Urea and glucose were related at all levels of GFR, and GFR 
was similar whether patients were hyper- or normoglycaemic. This is in agreement with the 
recent observation that, in comparison to the pretransplant setting (30), GFR and IR correlate 
poorly after RTx (128). Alternatively, urea could represent an association between protein 
catabolism and glycaemia. As illustrated in Figure 2, several mechanisms could be operative. 
The glycaemic impact of protein catabolism may be extended to involve urea directly 
(Figure 2). An increasing body of evidence from human and animal studies lends credibility 
to the hypothesis that urea may in itself be diabetogenic. Glucose tolerance is temporarily 
normalized by dialysis in patients with ESRD, suggesting that uraemic IR involves a 
dialyzable solute such as urea (34;45;129). Urea levels correlate with IR in patients with CKD 
(130) and are lowered by low-protein diets, which have insulin-sensitizing effects in these 
patients (131). Administration of urea has been found to reduce glucose disposal in healthy 
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males (132), in stable CKD patients (36) as well as in mice(133). In the latter study, urea 
alone caused a similar degree of IR in healthy mice as that seen in nephrectomized controls. 
 
Figure 2. Associations linking protein and glucose metabolism 
A. Protein breakdown can lead to IR by promoting the release of amino acids (134). Surgery, glucocorticoids 
and chronic inflammation could induce IR and PHYG by promoting protein breakdown. B. IR can lead to 
protein breakdown and increments in urea. Protein breakdown is suppressed by insulin (135), correlates with 
IR in patients with ESRD (38;136) and is the main source of urea in humans. C. Urea may be diabetogenic 
(see text for references). D. Uraemia is considered a catabolic state. However, this may only apply to unstable 
or acidotic patients (137). E, F. Low protein diets reduce IR and urea levels (131) in addition to whole body 
proteolysis (138) in uraemic patients. Unfortunately, protein intake could not be assessed in our study. 
[Schematic figure created by HA Bergrem]. 
 
This diabetogenic effect was mediated by a urea-induced generation of reactive oxygen 
species, which resulted in impaired signalling downstream of the insulin receptor, and 
subsequently lead to IR (133). The proximal mechanism of urea-induced IR is likely to 
involve carbamylation, which describes the modification by urea-derived cyanate of protein 
or amino acid structure and function. Carbamylated amino acids reduce insulin sensitivity in 
vitro (37), and were proposed to have mediated the effect of urea on the generation of 
oxidative stress (133). These observations could provide an explanation for the association 
between urea and PHYG in our study, and also suggest that protein catabolism is an important 
component in the pathogenesis of not only pre-, but also posttransplant hyperglycaemia. 
With the possible exception of urea, PHYG was poorly correlated with parameters 
reflective of renal function. The GFR was similar whether patients did or did not have PHYG. 
Nonetheless, patients with PHYG appeared to have a slightly higher GFR when adjusting for 
age. This difference could represent a degree of hyperfiltration in our PHYG patients, which 
has been proposed to indicate early graft injury resulting from hyperinsulinaemia (139). None 
 38 
of calcium, phosphate, PTH or haemoglobin displayed an association with glycaemia, despite 
a number of reports suggesting that such associations might exist. Elevations in calcium have 
been associated with IR among non-diabetic elderly males (50). Low phosphate levels are 
common after RTx, and have been associated with IR in subjects without renal disease 
(43;140;141). Hyperparathyroidism has been found to impair  cell function in animals (49), 
while in humans, parathyroidectomy has been followed by increased (46;48), unchanged (42) 
or even reduced (52) insulin secretion. Correction of anaemia by erythropoietin has been 
found to ameliorate IR in hemodialysis patients (41). A number of factors could not be 
accounted for in our study, however, making it difficult to conclude that no associations were 
present. We did not measure IR, and had no data on vitamin D or FGF-23, both of which are 
confounders for the calcium- phosphate-PTH axis after RTx (142;143). 
 
9.2.3. Glycaemia long term after renal transplantation 
 
PHYG is typically manifested early after RTx, but often tends to regress with tapering of 
immunosuppression. In spite of this, the prevalence of PHYG seems high even long term after 
RTx. The OGTT-determined prevalence of PHYG in stable RTx recipients without known 
DM, most of whom were Caucasians, recently amounted to some 30-50% at 2-6 years after 
RTx (144-146). Similar to these reports, we performed an OGTT in stable RTx recipients 
without known DM at 5 years after RTx (Paper 3), but observed PHYG in less than 15% of 
our patients. Since our patients used twice the prednisolone dose that is commonly used 
today, it is tempting to speculate that CNI therapy, which was not applied in our study, may 
have contributed significantly to PHYG in the other reports. Early impairments in  cell 
function are associated with CNI therapy (76;77), and appear to reduce the likelihood that 
NODAT will be reversible over time (68;69;146). Alternatively, differences in age, BMI, 
GFR or other factors may have been operative. In any case, the discrepancy was not related to 
differences in the diagnostic criteria applied, since our findings were the same whether WHO 
or ADA criteria were used (not shown). 
 
9.2.4. Role of prednisolone in glycaemia after renal transplantation 
 
A large study recently reported that the diabetogenicity of prednisolone depended on the type 
of concomitant CNI therapy prescribed (147). In this study, the risk of NODAT increased 
with increasing prednisolone doses, but only in patients using tacrolimus. However, the 
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DIRECT study reported the very opposite finding, namely that prednisolone was only 
diabetogenic in patients using CsA (75). It is therefore unclear how and to what extent the 
interpretation of prednisolone effects might be confounded by CNI therapy (84). Until shown 
otherwise, CNIs and prednisolone are both considered important risk factors for NODAT 
(7;55;71). Despite the co-medication with CNI and tapering of steroid doses, prednisolone 
seems to be important even long term after RTx. This is suggested by most (144;148), 
although not all (145) reports addressing PHYG in stable RTx patients without known DM. 
Contrary to the majority of current studies, we were able to assess the effects of 
prednisolone with no possibility of confounding due to CNIs. In line with our hypothesis, we 
observed a linear relationship between the exposure to unbound prednisolone and 
postprandial glycaemia. Due to the intracellular location of the glucocorticoid receptor (GR), 
prednisolone effects are thought to be exerted by the unbound drug, and this is likely also the 
case for steroid-induced hyperglycaemia (78;149;150). In agreement, there was no association 
between glucose tolerance and the alternative measures of prednisolone exposure. The 
mechanisms for prednisolone action and relation to hyperglycaemia are illustrated in Figure 3. 
Animal studies have indicated that prednisolone may also impair  cell function (78). 
In humans, short courses of steroid result in an increase in ISec to compensate for the degree 
of IR. The inability to counteract steroid-induced IR with a sufficient ISec response was the 
key determinant for whether or not steroid intake resulted in an elevated 2h-PG during an 
OGTT (151). The contribution of IR and impaired ISec could not be assessed in our study. 
We observed a higher total AUC of prednisolone in females as compared to males in 
our study. This coincided with a higher weight adjusted dose and lower total clearance of 
prednisolone among females. While the total clearance of prednisolone normally increases 
with increasing dose (91), we observed that females had a low clearance despite receiving a 
high dose of prednisolone. This indicates that the difference in clearance was not dose related, 
but rather reflected other factors, such as GFR, which was lower in females. Aside from this, 
it is unclear to what extent our results may or may not have reflected gender per se.  
Recent observations have nonetheless indicated that the metabolism of glucocorticoids 
could display gender specific differences. Our finding that prednisolone tended to be more 
diabetogenic in males than in females may perhaps be taken to illustrate the existence of such 
differences. The activity and tissue distribution of 11--hydroxysteroid dehydrogenase type 1 
(11-HSD1), an enzyme responsible for the local reactivation of cortisol from inactive 
cortisone (Figure 3), is increasingly considered a key factor in modulating the local 
availability and metabolic effects of glucocorticoids (152-154). Transgenic mice that  
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Figure 3. Prednisolone action and relation to hyperglycaemia. 
 
Unbound prednisolone or other glucocorticoids (ligands) bind to the glucocorticoid receptor (GR), which is 
thereafter phosphorylated to become biologically active. Subsequent effects occur by genomic or non-genomic 
pathways. In a genomic pathway, the GR-ligand complex enters the nucleus to interact with the DNA strand, 
leading to activation (transactivation) or repression (transrepression) of gene transcription. It is thought that 
side effects (e.g. hyperglycaemia) are mainly mediated through transactivation, whereas desirable therapeutic 
effects primarily occur by transrepression, alternatively by non-genomic pathways, in which the GR-ligand 
complex modifies inflammatory substances without altering their gene transcription (78;149;150)1). 
         Transactivation can promote IR by various pathways (78;150)1). In skeletal muscle, proteins transcribed 
due to prednisolone-induced transactivation can interfere with insulin signalling, leading to IR by a post-
receptor defect. Alternatively, the same proteins may induce IR by first altering intra-myocellular protein or 
lipid metabolism (increased proteolysis and lipolysis). In the liver, prednisolone promotes HGO by inducing 
IR, by providing substrate for gluconeogenesis (increased proteolysis and lipolysis), or by directly increasing 
the transcription of rate-limiting gluconeogenic enzymes. Some of these enzymes have GR-ligand sensitive 
DNA promoter regions, suggesting that steroids have a direct impact on the hepatic production of glucose. In 
adipose tissue, prednisolone increases lipolysis, mobilizes fat from peripheral to visceral depots, and may alter 
the expression of adipokines  associated with IR .[Schematic figure created by HA Bergrem].  
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overexpress 11-HSD1 develop obesity and IR (155). In humans, the activity of 11-HSD1 is 
increased in obesity, and inhibition of the enzyme reduces hepatic glucose output in lean type 
2 diabetic males (152). Interestingly, the expression of 11-HSD1 in lean subjects was 
recently found to be significantly lower in female than in male subcutaneous adipose 
tissue(153). Since prednisolone is in part converted to its inactive counterpart, prednisone, 
upon administration (85), and prednisone is a substrate for 11-HSD1 (85;154), it is tempting 
to speculate that increased local reactivation of inert prednisone by 11--HSD1 in males could 
be responsible for the observed gender difference in our study. 
Prednisolone meets several of the requirements proposed for concentration monitoring 
strategies (87). In spite of this, therapeutic drug monitoring has not become clinical practice 
for prednisolone. Due to a short half-life, prednisolone does not reach steady-state using 
common regimens, and thus requires an AUC measurement. This is time consuming, but may 
be omitted if a time point can be identified at which the concentration provides a valid 
estimate for the AUC (limited sampling). A 2-hour post dose concentration was recently 
found to correlate well with the AUC of total prednisolone in RTx patients (156), but this has 
to our knowledge not been established for the unbound drug. In addition, the methods 
required to measure the unbound fraction of prednisolone have not been routinely available. 
For these reasons, it has been claimed that therapeutic drug monitoring may not be feasible 
for prednisolone (87). Nonetheless, the monitoring of cyclosporine faced very similar 
challenges 20 years ago (91). This suggests that the challenges related to prednisolone 
monitoring are not necessarily overwhelming. As suggested by Steiner (93), the paucity of 
studies examining the efficacy of concentration guided steroid therapy may partly reflect the 
relative absence of a commercial counter-advocacy against the withdrawal of steroids. 
Regardless of the reason for the lack of trials involving steroid monitoring, the variable results 
of steroid withdrawal studies indicate that our understanding of steroids remains insufficient 
to determine the best clinical application of steroids after RTx (71). Our findings could 
therefore strengthen the rationale for measuring prednisolone concentrations in forthcoming 
studies. 
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10. CONCLUSIONS 
 
Undiagnosed DM and hyperglycaemia were prevalent in Caucasian RTx candidates without 
known DM at the time of referral for RTx. The OGTT was paramount to detect pretransplant 
DM in these patients. Unlike A1C, FPG helped predict the occurrence of a diabetic OGTT. 
When screening for DM, the pretransplant OGTT may be omitted, with only a small risk of 
misclassification, if FPG is below 5.1 mmol/L in Caucasian RTx candidates (Paper 1). 
 
The occurrence of PHYG early after RTx was reflective of elevations in glycaemia occurring 
before RTx, especially when these were evaluated using 2h-PG. PHYG displayed a strong 
and independent association with posttransplant levels of urea (Paper 2). 
 
The association between prednisolone exposure and glucose tolerance in stable RTx patients 
was more precisely evaluated using the unbound AUC as compared to the daily dose of 
prednisolone, at least in males (Paper 3). 
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11. IMPLICATIONS AND FUTURE PERSPECTIVES 
 
We have proposed a strategy that may well be helpful for identifying undiagnosed DM in 
Caucasian RTx candidates without prior DM (Paper 1). The clinical importance of this result 
is nonetheless unclear. It is not known to what extent it is important to detect hyperglycaemia 
before RTx, let alone whether undiagnosed DM is a more important entity as compared to 
intermediate hyperglycaemia. We observed that even non-diabetic elevations in pretransplant 
glucose predicted an increased risk of PHYG (Paper 2). It is therefore possible that even non-
diabetic degrees of pretransplant hyperglycaemia can have implications after RTx. Future 
studies should explore whether or not the risk of adverse posttransplant outcomes begins to 
rise at a discrete level of pretransplant glucose. These outcomes should include not only 
PHYG, but also endpoints such as cardiovascular disease and patient and graft survival. 
 
The association between PHYG and urea levels has not been described previously (Paper 2). 
Although the direction of this relationship is unclear, it could represent a novel link between 
uraemic and posttransplant hyperglycaemia. Studies should attempt to explore whether 
pretransplant or serial early posttransplant urea levels are predictive of PHYG. Measurements 
of protein and insulin metabolism would be of advantage in this context. 
 
We were able to document the proposed association between the exposure to unbound 
prednisolone and glucose tolerance without CNI interference. Studies should explore whether 
this relationship is also present during concomitant CNI therapy. An important goal should be 
to explore the feasibility of a limited sampling strategy for unbound prednisolone. This may 
subsequently help identify concentration levels associated with improved outcomes. 
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